Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
The purpose of this study is to demonstrate the efficacy and safety of AR101 through reduction in clinical reactivity to peanut allergen in peanut-allergic children and adults.
This is an international, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of AR101 in a characterized desensitization oral immunotherapy regimen in peanut-allergic individuals.
Key Inclusion Criteria:
UniCAPâ„¢*: a laboratory system for routine diagnostic testing of allergy and tool for basic studies on allergens and antibodies
PRACTALL**: PRACTical issues in ALLergology Joint United States/European Union Initiative
Key Exclusion Criteria:
Long Beach, California 90806, United States
Mission Viejo, California 92691, United States
Mountain View, California 94040, United States
Tampa, Florida 33613, United States
New York, New York 10029, United States
Chapel Hill, North Carolina 27599, United States
Philadelphia, Pennsylvania 19104, United States